B
BioLineRx Ltd D
D
BLRX
4.31000
USD
-0.18
(-4.01%)
مغلق
حجم التداول
1,835
الربح لكل سهم
0
العائد الربحي
-
P/E
-1
حجم السوق
16,037,523
الأخبار المقالات
العنوان: BioLineRx Ltd
القطاع: Healthcare
الصناعة: Biotechnology
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.